기사

(Photo = prodizen)

The Korea Industry Awards is an event hosted by the Dong-A Ilbo and supported by major government ministries including the Ministry of Trade, Industry and Energy, the Ministry of SMEs and Startups, and the Ministry of Science and ICT. It recognizes outstanding companies that have contributed to national economic and industrial development through differentiated technologies and management innovation. Prodizen was highly evaluated for its major achievements, including the commercialization of PRP (platelet-rich plasma), the registration of three new medical technologies, and exports to more than 30 countries, earning the honor of this grand prize.

Prodizen’s business history closely aligns with the development of PRP technology in Korea. Founded in 1998, its subsidiary Medisarang commercialized Korea’s first PRP product in 2008 and registered it with the Ministry of Food and Drug Safety. PRP is a medical technology that involves collecting a patient’s own blood, separating platelet-derived growth factors through centrifugation, and reapplying them to the affected area. All manufacturing is handled by Medisarang.

In addition, through industry-academia R&D collaboration with Samsung Hospital, Catholic Hospital, and Chosun University Hospital, the company succeeded in registering a new medical technology in orthopedics in 2019. It later expanded its applications into ophthalmology and obstetrics and gynecology, achieving a total of three new medical technology registrations to date.

Its global market expansion is also noteworthy. In addition to obtaining U.S. FDA Class II clearance and European CE certification, the company became the first in Korea to complete registrations in both the United States and China, and is currently exporting its products to more than 30 countries. Based on these achievements, it received the “$1 Million Export Tower” award in 2023. Its technological foundation is also solid, with eight technical patents and four design patents. Through a sales agreement with Clarion Medical, the company aims to achieve over USD 3 million in exports by 2027.

CEO Sim Su-ja stated, “This award is the result of the efforts of our employees who have dedicated themselves to technological development and global market expansion. We will continue to do our best to enable more people to enjoy healthier lives through unwavering advancements in cell therapy technology.”

[BioTimes = Reporter Kim Ji-su] news@biotimes.co.kr